חזרה לתוצאות החיפוש

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1

מצבים רפואיים

PIK3CA Mutation · Solid Tumor, Adult · HER2-negative Breast Cancer · Breast Cancer · Metastatic Breast Cancer · Advanced Breast Cancer · Unresectable Solid Tumor

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • The University of Arizona Cancer Center, Tucson, Arizona, United States

  • University of California-San Diego, San Diego, California, United States

  • HealthONE, Denver, Colorado, United States

  • Yale University, New Haven, Connecticut, United States

  • Florida Cancer Specialists, Orlando, Florida, United States

  • Boca Raton Clinical Research (BRCR) Global, Plantation, Florida, United States

  • University of Chicago Medical Center, Chicago, Illinois, United States

  • Community Health Network, Indianapolis, Indiana, United States

  • Massachusetts General Hospital, Boston, Massachusetts, United States

  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

  • University of Michigan, Ann Arbor, Michigan, United States

  • Washington University School of Medicine St. Louis, St Louis, Missouri, United States

  • Renown Regional Medical Center, Reno, Nevada, United States

  • Rutgers University, New Brunswick, New Jersey, United States

  • NYU Langone, New York, New York, United States

  • Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York, United States

  • Memorial Sloan Kettering, New York, New York, United States

  • Tennessee Oncology, Nashville, Tennessee, United States

  • University of Texas Southwestern Medical Center, Dallas, Texas, United States

  • The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

  • University of Utah- Huntsman Cancer Center, Salt Lake City, Utah, United States

  • Inova Schar Cancer Center, Fairfax, Virginia, United States

  • NEXT Virginia, Fairfax, Virginia, United States

  • UW Carbone Cancer Center, Madison, Wisconsin, United States

  • St Vincents Hospital, Sydney, New South Wales, Australia

  • Peter MacCallum Cancer Center, Melbourne, Victoria, Australia

  • The Alfred Hospital, Melbourne, Victoria, Australia

  • Centre Léon Bérard, Lyon, Auvergne-Rhône-Alpes, France

  • Institute Bergonié, Bordeaux, France

  • Gustave Roussy, Villejuif, France

  • Istituto Europeo di Oncologia IRCCS, Milan, Italy

  • Vall d'Hebron Instituto de Oncologia, Barcelona, Barcelona, Spain

  • START Barcelona, Barcelona, Catalonia, Spain

  • Instituto Valenciano de Oncologia, Valencia, Valencia, Spain

  • Institut Catala D'Oncologia - Badalona (ICO Badalona), Barcelona, Spain

  • START Madrid - Hospital Fundacion Jimenez Diaz, Madrid, Spain

  • Hospital Universitario 12 de Octubre, Madrid, Spain

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)